Chemical structural novelty: on-targets and off-targets.
暂无分享,去创建一个
[1] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[2] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[3] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[4] L. Laurén,et al. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. , 1988, Pharmacology & toxicology.
[5] Ajay N. Jain,et al. Effects of inductive bias on computational evaluations of ligand-based modeling and on drug discovery , 2008, J. Comput. Aided Mol. Des..
[6] Ajay N. Jain,et al. Molecular Shape and Medicinal Chemistry: A Perspective , 2010, Journal of medicinal chemistry.
[7] B. Silvestrini. Beyond the limits of typical antidepressants , 2004, Psychopharmacology.
[8] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[9] Glenn Shafer,et al. The combination of evidence , 1986, Int. J. Intell. Syst..
[10] R. Kuhn. The treatment of depressive states with G 22355 (imipramine hydrochloride). , 1958, The American journal of psychiatry.
[11] Gert Vriend,et al. Collecting and harvesting biological data: the GPCRDB and NucleaRDB information systems , 2001, Nucleic Acids Res..
[12] Xi Chen,et al. The Binding Database: data management and interface design , 2002, Bioinform..
[13] Anne W. Schmidt,et al. Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. , 1991, Journal of medicinal chemistry.
[14] Elliott Richelson,et al. Studies on Muscarinic Binding Sites in Human Brain Identified with [3H]Pirenzepine , 1986, Journal of neurochemistry.
[15] E. Brown,et al. The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.
[16] Ajay N. Jain,et al. Customizing scoring functions for docking , 2008, J. Comput. Aided Mol. Des..
[17] J Coupet,et al. Interaction of amoxapine with muscarinic cholinergic receptors: an in vitro assessment. , 1985, European journal of pharmacology.
[18] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[19] J. Overall,et al. CONTROLLED COMPARISON OF AMITRIPTYLINE, IMIPRAMINE AND PLACEBO IN HOSPITALIZED DEPRESSED PATIENTS , 1964, The Journal of nervous and mental disease.
[20] Ajay N. Jain,et al. Parameter estimation for scoring protein-ligand interactions using negative training data. , 2006, Journal of medicinal chemistry.
[21] S. Mascarella,et al. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists. , 1998, Journal of medicinal chemistry.
[22] R. Mach,et al. N-hydroxyalkyl derivatives of 3 beta-phenyltropane and 1-methylspiro[1H-indoline-3,4'-piperidine]: vesamicol analogues with affinity for monoamine transporters. , 1997, Journal of medicinal chemistry.
[23] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[24] Ajay N. Jain,et al. Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.
[25] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[26] Darren R. Flower,et al. On the Properties of Bit String-Based Measures of Chemical Similarity , 1998, J. Chem. Inf. Comput. Sci..
[27] Ajay N. Jain. Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition , 2000, J. Comput. Aided Mol. Des..
[28] G. Gintant,et al. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. , 2004, Journal of molecular and cellular cardiology.
[29] Ajay N. Jain,et al. Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.
[30] Christoph Steinbeck,et al. Chemical Entities of Biological Interest: an update , 2009, Nucleic Acids Res..
[31] Yvonne C. Martin,et al. Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..
[32] Tudor I. Oprea,et al. ChemProt: a disease chemical biology database , 2010, Nucleic Acids Res..
[33] J. Enokizono,et al. Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists. , 2007, Bioorganic & medicinal chemistry letters.
[34] E. R. Whittemore,et al. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition. , 1997, The Journal of pharmacology and experimental therapeutics.
[35] Bin Chen,et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..
[36] J. A. Jablonowski,et al. The first potent and selective non-imidazole human histamine H4 receptor antagonists. , 2003, Journal of medicinal chemistry.
[37] S. Snyder,et al. Structural determinants of sigma receptor affinity. , 1987, Molecular pharmacology.